Our Network Tagrisso plus chemotherapy reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and brain metastases at baseline Tags: #Research #Oncology #Medical Oncology #Clinical research #AstraZeneca 59% of these patients treated with Tagrisso plus chemotherapy had complete brain tumour responses in FLAURA2 Phase III trial.
